Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
zaltenibart (OMS906) / Omeros
NCT06298955: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria	Recruiting	2	25	Europe, RoW	OMS906 study drug	Omeros Corporation	Paroxysmal Nocturnal Hemoglobinuria	12/26	04/27
NCT06209736: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN	Recruiting	2	20	Europe, RoW	OMS906 study drug, OMS906	Omeros Corporation	C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis	01/25	04/26
OMS906-PNH-001, NCT05972967: Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab	Active, not recruiting	2	12	Europe	OMS906 Study Drug - 3 mg/kg, OMS906 Study Drug - 5 mg/kg, Ravulizumab	Omeros Corporation	Paroxysmal Nocturnal Hemoglobinuria	05/25	07/25
OMS906-PNH-002, NCT05889299: Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria	Recruiting	1b	10	RoW	OMS906 study drug	Omeros Corporation	Paroxysmal Nocturnal Hemoglobinuria	10/23	06/24